Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00984256 · ClinicalTrials.gov registry record · Phase 2
Weekly Dosing of Malarone ® for Prevention of Malaria
A Phase 2 study of Malaria, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00984256: Completed Phase 2 study of Malaria, sponsored by U.S. Army Medical Research and Development Command.
NCT00984256 is a Phase 2 study of Malaria that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 35 participants, below the 257-participant average among 27 other Malaria trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00984256, a Phase 2 study of Malaria, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether Malarone ®, which is a drug approved to prevent malaria when taken daily, will still effectively prevent malaria if taken weekly.
Primary Outcome
Number of participants with prophylactic efficacy was determined by the absence of cases of malaria parasitemia, defined as microscopically detectable parasitemia by Giemsa-stained thick smears, in those receiving any dose of Malarone as compared to the control (no treatment) group
Conditions Studied
Interventions
- DRUG Atovaquone Proguanil
- OTHER Procedure - malaria challenge
Study Locations (1)
Maryland
- Walter Reed Army Institute of Research - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
What the finished NCT00984256 record still lists
NCT00984256 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 257-participant average among 27 other Malaria trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 2 interventions - of which Atovaquone Proguanil is the first listed.
NCT00984256 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00984256 about?
NCT00984256 is a clinical study titled "Weekly Dosing of Malarone ® for Prevention of Malaria". The purpose of this study is to determine whether Malarone ®, which is a drug approved to prevent malaria when taken daily, will still effectively prevent malaria if taken weekly.
What is the current status of trial NCT00984256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2009-09. Estimated completion is 2010-04.
What conditions does trial NCT00984256 study?
This clinical trial studies the following conditions: Malaria.
What interventions are being tested in trial NCT00984256?
The interventions under investigation include: Atovaquone Proguanil (DRUG), Procedure - malaria challenge (OTHER).
Who is sponsoring clinical trial NCT00984256?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00984256 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00984256's enrollment target sits among peer trials
35 19th of 27 higher than 9 of 27 other Malaria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malaria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults
COMPLETED · Phase 2
-
Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults
COMPLETED · Phase 2
-
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
RECRUITING
-
Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants
RECRUITING
-
Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection
RECRUITING
-
A Study of Oral E1018 in Healthy Adult Participants
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia